310 related articles for article (PubMed ID: 17409441)
1. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
2. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death.
Blum R; Jacob-Hirsch J; Amariglio N; Rechavi G; Kloog Y
Cancer Res; 2005 Feb; 65(3):999-1006. PubMed ID: 15705901
[TBL] [Abstract][Full Text] [Related]
3. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
4. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats.
da Silva Morais A; Saliez A; Leclercq I; Horsmans Y; Stärkel P
Clin Sci (Lond); 2008 Jan; 114(1):73-83. PubMed ID: 17678500
[TBL] [Abstract][Full Text] [Related]
6. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y
J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665
[TBL] [Abstract][Full Text] [Related]
7. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
8. D-Serine exposure resulted in gene expression changes indicative of activation of fibrogenic pathways and down-regulation of energy metabolism and oxidative stress response.
Soto A; DelRaso NJ; Schlager JJ; Chan VT
Toxicology; 2008 Jan; 243(1-2):177-92. PubMed ID: 18061331
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor.
George J; Sack J; Barshack I; Keren P; Goldberg I; Haklai R; Elad-Sfadia G; Kloog Y; Keren G
Arterioscler Thromb Vasc Biol; 2004 Feb; 24(2):363-8. PubMed ID: 14670932
[TBL] [Abstract][Full Text] [Related]
10. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
Yaari-Stark S; Shaked M; Nevo-Caspi Y; Jacob-Hircsh J; Shamir R; Rechavi G; Kloog Y
Int J Cancer; 2010 May; 126(10):2268-81. PubMed ID: 19998334
[TBL] [Abstract][Full Text] [Related]
11. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice.
Mor A; Kloog Y; Keren G; George J
Eur J Pharmacol; 2009 Aug; 616(1-3):301-5. PubMed ID: 19527709
[TBL] [Abstract][Full Text] [Related]
12. Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
Stärkel P; Charette N; Borbath I; Schneider-Merck T; De Saeger C; Abarca J; Leclercq I; Horsmans Y
Mol Carcinog; 2012 Oct; 51(10):816-25. PubMed ID: 21882255
[TBL] [Abstract][Full Text] [Related]
13. Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid.
Reif S; Aeed H; Shilo Y; Reich R; Kloog Y; Kweon YO; Bruck R
J Hepatol; 2004 Aug; 41(2):235-41. PubMed ID: 15288472
[TBL] [Abstract][Full Text] [Related]
14. Farnesylthiosalicylic acid induces caspase activation and apoptosis in glioblastoma cells.
Amos S; Redpath GT; Polar G; McPheson R; Schiff D; Hussaini IM
Cell Death Differ; 2006 Apr; 13(4):642-51. PubMed ID: 16239932
[TBL] [Abstract][Full Text] [Related]
15. Ras inhibition attenuates myocardial ischemia-reperfusion injury.
Pando R; Cheporko Y; Haklai R; Maysel-Auslender S; Keren G; George J; Porat E; Sagie A; Kloog Y; Hochhauser E
Biochem Pharmacol; 2009 May; 77(10):1593-601. PubMed ID: 19426696
[TBL] [Abstract][Full Text] [Related]
16. Activated H-Ras regulates hematopoietic cell survival by modulating Survivin.
Fukuda S; Pelus LM
Biochem Biophys Res Commun; 2004 Oct; 323(2):636-44. PubMed ID: 15369798
[TBL] [Abstract][Full Text] [Related]
17. E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition.
Blum R; Nakdimon I; Goldberg L; Elkon R; Shamir R; Rechavi G; Kloog Y
Int J Cancer; 2006 Aug; 119(3):527-38. PubMed ID: 16496386
[TBL] [Abstract][Full Text] [Related]
18. Ras chaperones: new targets for cancer and immunotherapy.
Kloog Y; Elad-Sfadia G; Haklai R; Mor A
Enzymes; 2013; 33 Pt A():267-89. PubMed ID: 25033809
[TBL] [Abstract][Full Text] [Related]
19. The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model.
Shohami E; Yatsiv I; Alexandrovich A; Haklai R; Elad-Sfadia G; Grossman R; Biegon A; Kloog Y
J Cereb Blood Flow Metab; 2003 Jun; 23(6):728-38. PubMed ID: 12796721
[TBL] [Abstract][Full Text] [Related]
20. The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.
Schneider-Merck T; Borbath I; Charette N; De Saeger C; Abarca J; Leclercq I; Horsmans Y; Stärkel P
Eur J Cancer; 2009 Jul; 45(11):2050-60. PubMed ID: 19427195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
